Transition Therapeutics Inc. to Present at Upcoming Conferences



    TORONTO, April 2 /CNW/ - Transition Therapeutics Inc. ("Transition")
(TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive
Officer of Transition will be presenting at two upcoming conferences:

    Leerink Swann & Company/MEDACorp Alzheimer's Disease Roundtable
    Conference on Tuesday April 3, 2007 at 10:45am Eastern Time at Le Parker
    Meridien Hotel in New York City

    CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals
    Conference on Thursday April 12, 2007 at 10:55am Eastern Time at the
    Millennium Broadway Hotel in New York City

    All presentations will be webcast and accessible from Transition's
website at www.transitiontherapeutics.com. Each webcast will also be available
for replay on the Company's website for one week following the corresponding
conference. To ensure a timely connection to a webcast, it is recommended that
users register at least 15 minutes prior to the scheduled start time.

    About Transition

    Transition is a biopharmaceutical company, developing novel therapeutics
for disease indications with large markets. Transition's lead products include
AZD-103 for the treatment of Alzheimer's disease and regenerative therapies
E1-I.N.T.(TM) and GLP1-I.N.T.(TM) for the treatment of diabetes. Transition
has an emerging pipeline of preclinical drug candidates developed using its
proprietary drug discovery engine. Transition's shares are listed on the
Toronto Stock Exchange under the symbol "TTH". For additional information
about the company, please visit www.transitiontherapeutics.com.

    Notice to Readers: Information contained in our press releases should be
considered accurate only as of the date of the release and may be superseded
by more recent information we have disclosed in later press releases, filings
with the OSC or otherwise. Press releases may contain forward-looking
statements based on the expectations of our management as of the date of the
release. Actual results may materially differ based on many factors, including
those described in the press releases.
    %SEDAR: 00015806E




For further information:

For further information: www.transitiontherapeutics.com.; Dr. Tony Cruz,
Chief Executive Officer, Transition Therapeutics Inc, Phone: (416) 260-7770,
x.223, tcruz@transitiontherapeutics.com; Mr. Elie Farah, CFO and VP Corporate
Development, Transition Therapeutics Inc., Phone: (416) 260-7770, x.203,
efarah@transitiontherapeutics.com

Organization Profile

Transition Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890